Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Phase III, randomized controlled trial to evaluate lot consistency of a trivalent subunit egg-based influenza vaccine in adults.

Rivera L, Mazara S, Vargas M, Fragapane E, Casula D, Groth N.

Vaccine. 2012 Jul 27;30(35):5285-92. doi: 10.1016/j.vaccine.2012.05.021.

PMID:
22659448
2.

Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.

Tregnaghi MW, Stamboulian D, Vanadía PC, Tregnaghi JP, Calvari M, Fragapane E, Casula D, Pellegrini M, Groth N.

Viral Immunol. 2012 Jun;25(3):216-25. doi: 10.1089/vim.2011.0063.

PMID:
22691101
3.

Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.

Song JY, Cheong HJ, Lee J, Wie SH, Park KH, Kee SY, Jeong HW, Kim YS, Noh JY, Choi WS, Park DW, Sohn JW, Kim WJ.

Hum Vaccin Immunother. 2014;10(10):2958-64. doi: 10.4161/21645515.2014.970950.

PMID:
25483462
4.
5.

Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.

Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.

Pediatr Infect Dis J. 2012 May;31(5):494-500. doi: 10.1097/INF.0b013e31824bb179.

PMID:
22301476
6.

Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.

Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M.

Vaccine. 2015 May 15;33(21):2485-92. doi: 10.1016/j.vaccine.2015.03.065.

7.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099.

PMID:
21816199
8.

Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.

Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.

Vaccine. 2012 Jul 13;30(33):5030-7. doi: 10.1016/j.vaccine.2012.03.053.

PMID:
22472791
9.

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.

Ambrozaitis A, Groth N, Bugarini R, Sparacio V, Podda A, Lattanzi M.

Vaccine. 2009 Oct 9;27(43):6022-9. doi: 10.1016/j.vaccine.2009.07.083.

PMID:
19666152
10.

Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.

Zangwill KM, Droge J, Mendelman P, Marcy SM, Partridge S, Chiu CY, Jing J, Chang SJ, Cho I, Ward JI.

Pediatr Infect Dis J. 2001 Aug;20(8):740-6.

PMID:
11734734
11.

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.

Vaccine. 2012 May 14;30(23):3470-7. doi: 10.1016/j.vaccine.2012.03.017.

PMID:
22446638
12.

Response to a monovalent 2009 influenza A (H1N1) vaccine.

Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.

N Engl J Med. 2009 Dec 17;361(25):2405-13. doi: 10.1056/NEJMoa0907413.

13.

Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.

Lopez P, Caicedo Y, Sierra A, Tilman S, Banzhoff A, Clemens R.

J Infect Dis. 2011 Jun 15;203(12):1719-28. doi: 10.1093/infdis/jir191.

PMID:
21606530
14.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.

Vaccine. 2010 Feb 17;28(7):1740-5. doi: 10.1016/j.vaccine.2009.12.014.

PMID:
20034605
15.

Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.

Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.

Vaccine. 2012 Jun 22;30(30):4543-51. doi: 10.1016/j.vaccine.2012.03.061.

PMID:
22475864
16.

Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.

Della Cioppa G, Nicolay U, Lindert K, Leroux-Roels G, Clement F, Castellino F, Galli G, Groth N, Del Giudice G.

Hum Vaccin Immunother. 2012 Feb;8(2):216-27. doi: 10.4161/hv.18445.

PMID:
22426371
17.

Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.

Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.

Vaccine. 2011 Feb 11;29(8):1569-75. doi: 10.1016/j.vaccine.2010.12.116.

PMID:
21219979
18.

A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.

Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.

Vaccine. 2012 Jul 6;30(32):4820-7. doi: 10.1016/j.vaccine.2012.05.013.

PMID:
22626675
19.

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

Szymczakiewicz-Multanowska A, Groth N, Bugarini R, Lattanzi M, Casula D, Hilbert A, Tsai T, Podda A.

J Infect Dis. 2009 Sep 15;200(6):841-8. doi: 10.1086/605505. Erratum in: J Infect Dis. 2009 Dec 1;200(11):1801-2.

PMID:
19673651
20.
Items per page

Supplemental Content

Support Center